Learn How Stem Cell Therapy Is Being Used Right Here in North Texas
http://www.innovationsstemcellcenter.com Call: 214.420.7970 Facebook: https://www.facebook.com/innovationsmedical Twitter: https://twitter.com/dallasdrj Instagram: http://instagram.com/drbilljo...

By: dallasdrj

Read more here:
Learn How Stem Cell Therapy Is Being Used Right Here in North Texas - Video

Can brain damage caused during birth be ever reversed? Is it possible to repair the damaged brain tissues among children, who suffer from Cerebral Palsy (CP)?

So far, the treatment option for CP is to manage the symptoms of the ailment. However, in recent times, scientists and researchers worldwide have started to explore stem cell therapy as a potential treatment option for CP patients.

Can stem cells reverse the brain damage, which is the sole cause for CP among children? Our research on over 100 CP patients and stem cell therapy has been very encouraging. The patients, who underwent stem cell therapy, have displayed huge improvement in CP symptoms, says Professor and Head of Neurosurgery, LTM Medical College, Mumbai, Alok Sharma.

The neurosurgeon, who is taking part in an international conference on CP in Hyderabad this weekend, said that doctors are not concentrating on treating the brain damage.

The current treatment options available to help patients are only to mange symptoms and nobody tries to repair the underlying damage to the brain tissue. Therefore, developing a standard therapeutic approach for CP through stem cells is the need of the hour, he said.

The results from the stem cell therapy on CP patients conducted by Dr. Aloks team were recently published in Neurogens chapter on Stem cell therapy for cerebral palsy A Novel Option in a book titled Cerebral Palsy Challenges For the Future. According to the neurosurgeon, the patients after therapy had improvements in their speech, balance, upper and lower limb activity and movement.

While for stem cell research, many prefer cord blood banking, Dr. Alok pointed out that they have used stem cells from the adults derived from the bone marrow. The transplanted stem cells have the ability to migrate to the area of the damaged tissue in the brain and home-in on those affected areas to help repair the damage. Stem cells release substance that stimulates natural growth, which decreases the process of damage of the brain, Dr. Alok explained.

The researcher, who has started NeuroGen Brain and Spine Institute in Mumbai to conduct stem cell research, pointed out that stem cell therapy and other rehabilitation programmes should be encouraged for the benefit of CP patients. The positive changes that we recorded in our patients were not just restricted to their symptoms but also constructive change in brain metabolism observed through PET-CT scans, he explained. Dr. Alok Sharma can be reached at: alok276@gmail.com

Read the original:
Fighting CP through stem cell therapy

10.10.2014 - (idw) Fraunhofer-Gesellschaft

From 9-10 October 2014 around 200 scientists met at the Leipzig Fraunhofer Institute for Cell Therapy and Immunology for the ninth Fraunhofer Life Science Symposium. Held every two years, this year the event focused on the theme "Medicinal Cell Products and Stem Cells for Medicinal Applications". In recent years biomedical research has revealed numerous promising new approaches for the prevention and treatment of serious illnesses. The issue of stem cells plays a key role in this. With the symposium the Fraunhofer IZI offers international scientists a platform on which they can discuss the latest developments in this field.

The scientific program encompasses three major subject areas: production, manufacture and application. In the first section a paper presented by Sarah Ferber (Centre for Stem Cells, Regenerative Medicine and Tissue Engineering, Sheba Medical Center, Tel Hashomer, Israel) was one major point of interest: "Reprogramming the endocrine pancreas; autologous cell replacement therapy for diabetic patients". She spoke about the possibilities for transforming liver cells into insulin-producing cells. In the future this method could possibly be used to help patients with type 1 diabetes, where the misdirected immune system destroys the body's own insulin-producing beta cells of the pancreas.

The Fraunhofer Life Science Symposium brings together up to 200 participants from academic and clinical institutions to discuss the various focal points concerning new technologies, trends and developments. It is organized by the Fraunhofer Institute for Cell Therapy and Immunology IZI. For further information see http://www.fs-leipzig.com. Weitere Informationen:http://www.fs-leipzig.comhttp://www.izi.fraunhofer.de

More here:
Experts discuss new developments in the field of stem cell research and cell therapy

Ageless Derma Apple Stem Cell Skincare
This active ingredient won the Best Active Ingredient prize in European Innovation in 2008. Stem Cells derived from a rare Swiss Apple are part of the rev...

By: Rokshana popal

See original here:
Ageless Derma Apple Stem Cell Skincare - Video

CAMBRIDGE, Mass., Oct. 9 (UPI) -- Patients with type 1 diabetes lack the insulin-producing cells that keep blood glucose levels in check. Currently, these patients must use insulin pumps or daily hormone injections to keep levels stable.

But in a recent breakthrough in laboratories at Harvard University, researchers came upon a new technique for transforming stem cells into pancreatic beta cells that respond to glucose levels and produce insulin when necessary. The breakthrough could lead to new less invasive, more hands-off treatment for diabetes.

Remarkably, the new technique -- a complex process which involves turning on and off specific genes and takes about 40 days and six precise steps to complete -- was replicated not only on embryonic stem cells but also on human skin cells reprogrammed to act in a stem-cell-like manner. This revelation allows scientists to produce millions of insulin-producing cells while avoiding the ethical dilemmas attached to traditional stem cell research.

Previous attempts to convert stem cells into insulin-producers have proven moderately successful, but these cells mostly produced insulin at will, unable to adjust their output on the fly. The latest techniques -- developed by Douglas Melton, co-director of the Harvard Stem Cell Institute, and his research colleagues -- produce insulin cells that react to glucose spikes by upping production, and lowering insulin output when there's not excess sugar to break down.

The breakthrough has already shown significant promise when used on lab mice. Diabetic mice who received a transplant of the stem cell beta cells had improved blood sugar levels, and were shown to be capable of breaking down sugar.

"We can cure their diabetes right away -- in less than 10 days," Melton told NPR. "This finding provides a kind of unprecedented cell source that could be used for cell transplantation therapy in diabetes."

But there's still one major issue. For reasons doctors still don't understand, the beta cells in humans with diabetes are attacked by the body's immune system. Researchers like Melton still have to figure out a way to protect the new beta cells from being killed -- otherwise the breakthrough won't become anything more than another short-term solution.

"It's taken me 10 to 15 years to get to this point, and I consider this a major step forward," Melton told TIME. "But the longer term plan includes finding ways to protect these cells, and we haven't solved that problem yet."

2014 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.

More here:
Harvard researchers grow insulin-producing stem cells

October 10, 2014 - 17:56 AMT

PanARMENIAN.Net - In what could be a major breakthrough for diabetes treatment, scientists have discovered a way to drastically alter human embryonic stem cells, transforming them into cells that produce and release insulin, RT said.

Developed by researchers at Harvard University, the innovative new technique involves essentially recreating the formation process of beta cells, which are located in the pancreas and secrete insulin. By stimulating certain genes in a certain order, the Boston Globe reports that scientists were able to charm embryonic stem cells and even altered skin cells into becoming beta cells.

The whole process took 15 years of work, but now lead researcher Doug Melton says the team can create hundreds of millions of these makeshift beta cells, and theyre hoping to transplant them into humans starting in the next few years.

"We are reporting the ability to make hundreds of millions of cells the cell that can read the amount of sugar in the blood which appears following a meal and then squirts out or secretes just the right amount of insulin," Melton told NPR.

There are 29.1 million people in the United States believed to have diabetes, according to statistics by the Centers for Disease Control and Prevention dating back to 2012. Thats 9.3 percent of the entire population.

Currently, diabetes patients must rely on insulin shots to keep their blood-sugar levels stable, a process that involves continual monitoring and attentiveness. Failure to efficiently control these levels can cause some patients to go blind, suffer from nerve damage and heart attacks, and even lose limbs. If Meltons beta cell creation process can be successfully applied to humans, it could eliminate the need for such constant check-ups, since the cells would be doing all the monitoring. Already, there are positive signs moving forward: the transplanted cells have worked wonders on mice, quickly stabilizing their insulin levels.

"We can cure their diabetes right away in less than 10 days," Melton said to NPR. "This finding provides a kind of unprecedented cell source that could be used for cell transplantation therapy in diabetes."

With mice successfully treated, the team is now working with a scientist in Chicago to put cells into primates, the Globe reported.

Even so, significant obstacles remain, particularly for those who have Type 1 diabetes. With this particular form of the disease, the human immune system actually targets and destroys insulin-producing beta cells in the pancreas, so Meltons team is looking into encasing cells inside of a protective shell in order to ensure their safety.

Read the rest here:
Harvard University scientists alter stem cells to make insulin

Research into a cure for diabetescould result in an end to insulin injections It has beenhailed as the biggest medical breakthrough since antibiotics Harvard researcher Doug Melton promised his children he'd find a cure Treatment involves making insulin-producing cells from stem cells Scientistshope to have human trials under way within a 'few years'

By Fiona Macrae for the Daily Mail

Published: 17:41 EST, 9 October 2014 | Updated: 04:45 EST, 10 October 2014

1.7k shares

152

View comments

Scientists have hailed stem-cell research into a cure for diabetes as potentially the biggest medical breakthrough since antibiotics.

It could result in an end to insulin injections, and to the disabling and deadly complications of the disease, such as strokes and heart attacks, blindness and kidney disease.

The treatment, which involves making insulin-producing cells from stem cells, was described as a 'phenomenal accomplishment' that will 'leave a dent in the history of diabetes'.

Scroll down for video

More:
Could this stem cell breakthrough offer an end to diabetes?

StemCells Inc. ( STEM ) announced that it has commenced a phase II proof-of-concept study, Pathway, which will use the company's proprietary human neural system stem cells (HuCNS-SC) platform for treating patients suffering from cervical spinal cord injury (SCI). The company's phase II trial is titled "Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury."

The randomized, controlled, single-blind study will evaluate the safety and efficacy of transplanting HuCNS-SC cells into patients with traumatic injury in the cervical region of the spinal cord. The study will evaluate patients for a period of 12 months post-enrollment.

We remind investors that earlier in the year, the company had reported encouraging interim results from a phase I/II thoracic SCI study. StemCells intends to present final data from the phase I/II study in mid-2015.

According to the press release issued by StemCells, nearly 1.3 million people in the U.S. have reported paralysis due to an SCI and about 56% of spinal cord injuries occur in the cervical region. Upon approval, the new treatment will provide significant benefits to patients suffering from cervical SCI considering the present lack of effective treatments.

Meanwhile, StemCells is currently evaluating HuCNS-SC cells for several other indications including dry age-related macular degeneration (AMD), Pelizeaus-Merzbacher disease (PMD) and Alzheimer's disease.

We expect investor focus to remain on pipeline updates.

StemCells currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Emergent BioSolutions, Inc. ( EBS ), Ligand Pharmaceuticals Inc. ( LGND ) and Medivation, Inc. ( MDVN ). All three carry a Zacks Rank #1 (Strong Buy).

STEMCELLS INC (STEM): Get Free Report

MEDIVATION INC (MDVN): Free Stock Analysis Report

LIGAND PHARMA-B (LGND): Free Stock Analysis Report

Read the rest here:
StemCells Starts Phase II Cervical Spinal Cord Injury Study - Analyst Blog

October 8, 2014

Image Caption: New genetic barcoding technology allows scientists to identify differences in origin between individual blood cells. Credit: Camargo Lab

Provided by Joseph Caputo, Harvard University

New technology that tracks the origin of blood cells challenges scientific dogma

A 7-year-project to develop a barcoding and tracking system for tissue stem cells has revealed previously unrecognized features of normal blood production: New data from Harvard Stem Cell Institute scientists at Boston Childrens Hospital suggests, surprisingly, that the billions of blood cells that we produce each day are made not by blood stem cells, but rather their less pluripotent descendants, called progenitor cells. The researchers hypothesize that blood comes from stable populations of different long-lived progenitor cells that are responsible for giving rise to specific blood cell types, while blood stem cells likely act as essential reserves.

The work, supported by a National Institutes of Health Directors New Innovator Award and published in Nature, suggests that progenitor cells could potentially be just as valuable as blood stem cells for blood regeneration therapies.

This new research challenges what textbooks have long read: That blood stem cells maintain the day-to-day renewal of blood, a conclusion drawn from their importance in re-establishing blood cell populations after bone marrow transplantsa fact that still remains true. But because of a lack of tools to study how blood forms in a normal context, nobody had been able to track the origin of blood cells without doing a transplant.

Boston Childrens Hospital scientist Fernando Camargo, PhD, and his postdoctoral fellow Jianlong Sun, PhD, addressed this problem with a tool that generates a unique barcode in the DNA of all blood stem cells and their progenitor cells in a mouse. When a tagged cell divides, all of its descendant cells possess the same barcode. This biological inventory system makes it possible to determine the number of stem cells/progenitors being used to make blood and how long they live, as well as answer fundamental questions about where individual blood cells come from.

Theres never been such a robust experimental method that could allow people to look at lineage relationships between mature cell types in the body without doing transplantation, Sun said. One of the major directions we can now go is to revisit the entire blood cell hierarchy and see how the current knowledge holds true when we use this internal labeling system.

People have tried using viruses to tag blood cells in the past, but the cells needed to be taken out of the body, infected, and re-transplanted, which raised a number of issues, said Camargo, who is a member of Childrens Stem Cell Program and an associate professor in Harvard Universitys Department of Stem Cell and Regenerative Biology. I wanted to figure out a way to label blood cells inside of the body, and the best idea I had was to use mobile genetic elements called transposons.

Read more:
Scientists Develop Barcoding Tool For Stem Cells

Ageless Derma Anti Aging Skin Care
This active ingredient won the Best Active Ingredient prize in European Innovation in 2008. Stem Cells derived from a rare Swiss Apple are part of the revolutionary technological designed...

By: Rokshana popal

Read more from the original source:
Ageless Derma Anti Aging Skin Care - Video

Hamish Gilbert - Development of a Stem Cell Therapy forRepair of the Degenerate Intervertebral Disc
Description.

By: FMHSGraduateSociety

More:
Hamish Gilbert - Development of a Stem Cell Therapy forRepair of the Degenerate Intervertebral Disc - Video

Arthritis of shoulder; results four years after stem cell therapy by Harry Adelson, N.D.
Heavy discusses his outcome four years out from his first bone marrow stem cell treatment for his arthritic shoulders and torn rotator cuffs by Harry Adelson, N.D. http://www.docereclinics.com.

By: Harry Adelson, N.D.

Read the rest here:
Arthritis of shoulder; results four years after stem cell therapy by Harry Adelson, N.D. - Video

Michael Scott, a ViaCyte vice president, holds the VC-01 device that holds progenitor cells that will mature to make insulin and other hormones.

More than ever before, stem cell therapies appear poised to transform medicine potentially curing heart disease, diabetes and paralyzing injuries, among other ailments.

But its also clear that such innovations will be very expensive.

How the government, insurers and patients will pay for what could be a flood of these new treatments drew the attention of more than 700 biomedical and health-care executives Tuesday at the 2014 Stem Cell Meeting on the Mesa.

The annual conference, held on La Jolla's Torrey Pines Mesa, will run through Thursday. It brings together the business and academic worlds of cell therapy, including but not limited to stem cell treatments.

In California alone, 131 clinical trials are taking place with stem cells, according to Clinicaltrials.gov, a government website that tracks clinical trials. Patients are being treated for conditions such as blindness from retinal diseases, HIV, leukemia, sickle cell disease, stroke and aging of skin.

The recent proliferation of clinical trials marks great progress toward the ultimate goal of getting new treatments to patients, said stem cell researcher Jeanne Loring, who directs the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla.

Its been a sea change from last year, said Loring, who is working with some colleagues in planning their own stem cell trial to treat Parkinsons disease.

Theyre developing replacement neurons grown from artificial embryonic stem cells called induced pluripotent stem cells. The process begins with cells derived from the skin of patients to be treated.

Home-grown milestone

Go here to see the original:
Stem cell treatments surging into clinic

A combined LifeSource blood drive and Be The Match bone marrow registry event will honor two local women battling different forms of leukemia from 8 a.m. to 2 p.m. Saturday, Oct. 11, at The Society of Danube Swabians, 625 E. Seegers Road, Des Plaines.

The event will co-honor Des Plaines resident Amy Charewicz, 24, and Prospect Heights resident Anni Mayer, who is a Society of Danube Swabians board member. Mayer, a St. Alphonsus Ligouri parishioner and national society youth group leader, has Myelodyplastic Syndrome, a blood cancer that prevents her bone marrow from making enough healthy blood cells. Charewicz has aggressive Acute Myeloblastic Leukemia, a disease that causes her bone marrow to produce abnormal white and red blood cells, as well as platelets.

The Northern Illinois University graduate will receive a stem cell transplant Thursday from a 23-year-old man located by Be the Match at Northwestern Memorial Hospital. "Amy has been fortunate to have what she needs available because others have donated and registered," says Doris Charewicz, her mother. "She wants to 'pay it forward' by increasing awareness of the need for both blood donors and stem cell donors."

Be The Match registrants are limited to ages 18-44 and don't need to preregister. Blood donor walk-ins are welcome, but appointments are preferred at (877) 543-3768 or http://www.lifesource.org using code 650B.

View post:
Bone marrow registry drive Saturday in Des Plaines

Henderson, NV (PRWEB) October 07, 2014

Stem cells from plants are becoming an increasingly popular way to turn the clock backward on skin aging. Hylunia's own light and silky Moisure Infusion contains plant stem cells and peptides that are thought to delay aging, making skin look softer smoother and younger.

Plant stem cells like the ones found in grapes are undifferentiated cells from the meristems of plants. Like human stem cells, they can replace damaged cells and renew themselves. Plant stem cells are cultured in labs, allowing scientists to have more control over the quality, quantity and purity of a plant's anti-aging substance.

Skin care stem cells are extracted from various plants, including tiny white Edelweiss flowers, a swamp plant called gotu kola, swiss apples, and raspberry cell cultures. Lilac and algae may also be used. Most of these products contain antioxidants and other chemicals that make skin look younger.

Hylunia's unique product features grape stem cells cultivated from the Gamay Teinturier Fraux grape from Burgundy, France. Their ingredient list explains that these grapes are "high in powerful antioxidants and [have] free radical scavenging capabilities."

The site adds that "The Grape Stem Cells contain special epigenetic factors and metabolites which are able to protect human stem cells against UV radiation and therefore delay aging." UV damage is responsible for up to 80% of skin aging.

Hylunia Moisture Infusion also contains peptides, which can boost collagen and block the neurotransmitters that contract the muscles that form wrinkles. They stimulate epidermal skin cells and increase skin healing and repair.

Hyluna's product contains Palmitoyl Trypeptide-5 (patented), which stimulates collagen synthesis to "strengthen skin and reduce the appearance of fine lines and wrinkles."

Hylunia is currently putting together a webinar about plant peptides for their professional customers like spa and salon owners. The webinar will be available soon.

Read the original:
Hylunia Educates Professional Customers on Anti-Aging Peptides and Stem Cells

PUBLIC RELEASE DATE:

6-Oct-2014

Contact: Sarah McDonnell s_mcd@mit.edu 617-253-8923 Massachusetts Institute of Technology @MITnews

CAMBRIDGE, MA -- Deep within the bone marrow resides a type of cells known as mesenchymal stem cells (MSCs). These immature cells can differentiate into cells that produce bone, cartilage, fat, or muscle a trait that scientists have tried to exploit for tissue repair.

In a new study that should make it easier to develop such stem-cell-based therapies, a team of researchers from MIT and the Singapore-MIT Alliance in Research and Technology (SMART) has identified three physical characteristics of MSCs that can distinguish them from other immature cells found in the bone marrow. Based on this information, they plan to create devices that could rapidly isolate MSCs, making it easier to generate enough stem cells to treat patients.

Until now, there has been no good way to separate MSCs from bone marrow cells that have already begun to differentiate into other cell types, but share the same molecules on the cell surface. This may be one reason why research results vary among labs, and why stem-cell treatments now in clinical trials are not as effective as they could be, says Krystyn Van Vliet, an MIT associate professor of materials science and engineering and biological engineering and a senior author of the paper, which appears in the Proceedings of the National Academy of Sciences this week.

"Some of the cells that you're putting in and calling stem cells are producing a beneficial therapeutic outcome, but many of the cells that you're putting in are not," Van Vliet says. "Our approach provides a way to purify or highly enrich for the stem cells in that population. You can now find the needles in the haystack and use them for human therapy."

Lead authors of the paper are W.C. Lee, a former graduate student at the National University of Singapore and SMART, and Hui Shi, a former SMART postdoc. Other authors are Jongyoon Han, an MIT professor of electrical engineering and biological engineering, SMART researchers Zhiyong Poon, L.M. Nyan, and Tanwi Kaushik, and National University of Singapore faculty members G.V. Shivashankar, J.K.Y. Chan, and C.T. Lim.

Physical markers

MSCs make up only a small percentage of cells in the bone marrow. Other immature cells found there include osteogenic cells, which have already begun the developmental path toward becoming cartilage- or bone-producing cells. Currently, researchers try to isolate MSCs based on protein markers found on the cell surfaces. However, these markers are not specific to MSCs and can also yield other types of immature cells that are more differentiated.

Excerpt from:
New technique allows scientists to find rare stem cells within bone marrow

VIEW GALLERY

The family of brave toddler Margot Martini launched a new bone marrow donor appeal this morning exactly a year after she was diagnosed with leukaemia.

Her relatives said the first Team Margot Stem Cell and Bone Marrow Awareness Day would be held in another 12 months, on Wednesday October 7, 2015.

The two-year-old underwent a bone marrow transplant in February after her dad, Yaser, from Essington, and mum Vicki launched a desperate appeal for help.

Margot Martini with mum Vicky

But she relapsed and her parents decided to end her treatment after being told her chances of survival were less than one per cent.

The awareness day is designed to promote awareness around the need for more potential stem cell donors to join the UK and worldwide registries.

Her family said they hoped mixed race people would sign up to plug a gaping hole on the lists.

Just sixty per cent of the 37,000 patients needing a stem cell donor worldwide receives a perfect match.

But that figure plunges to barely 20 per cent for those from black, Asian or ethnic minority communities.

View post:
Family of Margot Martini launch new stem cell and bone marrow appeal

By Jon Cohen October 6 at 5:00 PM

Researchers are closer to unraveling the mystery of how Timothy Ray Brown, the only human cured of HIV, defeated the virus, according to a new study. Although the work doesnt provide a definitive answer, it rules out one possible explanation.

Brown remains one of the most studied cases in the HIV epidemics history. In 2006, after living with the virus for 11 years and controlling his infection with antiretroviral drugs, he learned that he had developed acute myeloid leukemia. (The leukemia has no known relationship to HIV infection or treatment.) Chemotherapy failed, and the next year Brown received the first of two bone marrow transplants a common treatment for this cancer and ditched his antiretrovirals. (An American then living in Berlin, Brown has been known to researchers for years as the Berlin patient.

When HIV-infected people stop taking these drugs, levels of HIV typically skyrocket within weeks. Yet researchers scouring Browns blood over the past seven years have found only traces of the viral genetic material, none of which can replicate.

Today, researchers point to three factors that might independently or in combination have ridden Browns body of HIV. The first is the process of conditioning, in which doctors destroyed Browns immune system with chemotherapy and whole-body irradiation to prepare him for his bone marrow transplant.

Second, his oncologist, Gero Htter, took an extra step that he thought might not only cure the leukemia but also help rid Browns body of HIV. He found a bone marrow donor who had a rare mutation in a gene that cripples a key receptor on white blood cells that the virus uses to establish an infection.

The third possible explanation is that Browns new immune system attacked remnants of his old one that held HIV-infected cells, a process known as graft vs. host disease.

In the new study, a team led by immunologist Guido Silvestri of Emory University in Atlanta designed an unusual monkey experiment to test these possibilities.

Bone marrow transplants work because of stem cells. Modern techniques avoid actually aspirating bone marrow and instead can sift through blood and pluck out the stem cells needed for a transplant to engraft. So the researchers first drew blood from three rhesus macaque monkeys, removed stem cells and put the cells in storage. They then infected these animals and three control monkeys with a hybrid virus, known as SHIV, that contains parts of the simian and human AIDS viruses. All six animals soon began receiving antiretroviral drugs, and SHIV levels in the blood quickly dropped below the level of detection on standard tests, as expected.

A few months later, the three monkeys with stored stem cells underwent whole-body irradiation to condition their bodies and then had their own stem cells reinfused. After the cells engrafted, a process that took a few more months, the researchers stopped antiretrovirals in the three animals and in the three controls. SHIV quickly came screaming back in the three controls and two of the transplanted animals. (One of the transplanted monkeys did not have the virus rebound, but its kidneys failed and the researchers euthanized it.)

Read more:
How did the Berlin patient become cured of HIV?

(PRWEB UK) 7 October 2014

Stem cell treatments take place in countries all around the world every day. Thousands of lives have already been saved, and advancements in this area of medicine means that future healthcare treatments look set to further prolong and improve life.

But specialist stem cell bank BioEden warn that there is a risk of thinking of stem cell therapy in terms of the future alone. 'The need to have a stem cell match is vital', says Group CEO Mr Tony Veverka. 'Without access to a stem cell match, the work of stem cell scientists could be at risk. That is the reason why BioEden was set up, to ensure that anyone could bank and have access to their own stem cells. We also wanted to ensure that the brilliant work being carried out by stem cell scientists and medical professionals could continue unhindered'.

BioEden's services are being promoted by Health Care Professionals including specialist insurance intermediaries, and dentists. This week to highlight Stem Cell Awareness week, members of their specialist teams will be on the road visiting dentists, schools and healthcare insurance companies.

'Let's make everyone aware of the opportunities they have to store their own cells during stem cell awareness week. Perhaps we need to re name it Stem Cell Self-Awareness week'.

For more information visit http://www.bioeden.com

Read the original:
BioEden the specialist tooth stem cell bank plan to shake up public perception as Stem Cell Awareness week takes hold.

Step 1 - lupus / diabetes / alzheimers syrum - Take 5ml blood
Contact Josh@mexicoassistedliving.com for more information about this amazing stem cell medicine that is helping to treat people with lupus, anti-immune disorders, alzheimers, diabetes type...

By: Joshua Ketner

Visit link:
Step 1 - lupus / diabetes / alzheimers syrum - Take 5ml blood - Video